Combination of Gilead, Bristol-Myers Hepatitis C Drugs Show Promise in Study
Peter Loftus
Updated April 19, 2012 3:55 pm ET
A regimen combining experimental drugs from Gilead Sciences Inc. and Bristol-Myers Squibb Co. suppressed the hepatitis C virus in most patients four weeks after completing treatment, according to a new study.
In a separate study, Gilead said a combination of its drug, GS-7977, with an older drug, ribavirin, suppressed the liver-disease-causing virus in most patients four weeks after treatment.